The neuropeptides, monoamines and many drugs involved with modulating food intake and fat stores have reciprocal effects on sympathetic activity and thermogenesis. Both serotonin, acting through 5HT 1Ba2C receptors, and norepinephrine acting through b b 2 andaor b b 3 receptors reduce food intake and augment sympathetic activity. Neuropeptide Y, b b-endorphin, orexin, galanin and melanin concentrating hormone all increase food intake and, where tested, reduce sympathetic activity. In contrast, a larger number of peptides including cholecystokinin, corticotrophin-releasing hormoneaurocortin, enterostatin, leptin, CART and a-MSH reduce food intake and increase sympathetic activity. Nicotine, prostaglandin, dexfen¯uramine and sibutramine also have this reciprocal effect on feeding and sympathetic nervous system (SNS) activity. Chronic administration of neuropeptide Y (NPY) can produce chronically increased food intake and obesity. This syndrome is similar to the ventromedial hypothalamus (VMH) syndrome and suggests that NPY must be acting as an inhibitory signal to stimulate a feeding system and inhibit sympathetic activity. The melanocortin receptor system may be particularly important in modulating food intake, because a transgenic mouse which does not express melanocortin-4 receptors is massively overweight. Adrenal glucocorticoids are important in obesity since adrenalectomy will reverse or prevent the development of all forms of obesity. The clinical importance of the sympathetic nervous system and food intake is emphasized by the inverse relation of sympathetic activity and body fat. The inhibition of food intake, lower body fat stores and higher energy expenditure in smokers also support this hypothesis. The reciprocal relationship between food intake and sympathetic activity is robust, suggesting that b b receptors in the periphery and brain may be involved in the control of feeding and a reduction in food intake in humans accounts for most of the weight loss with ephedrine and caffeine. We conclude that the inhibition of feeding by activating the SNS is an important satiety system which helps regulate body fat stores.
Introduction
The underlying hypothesis for this work is that food intake and the sympathetic nervous system form a feedback system, which produces satiety, thermogenesis and lower body fat and that b 3 adrenergic receptors are involved peripherally and b 2 adrenergic receptors are involved centrally in this system. 1 ± 3 Thus, low sympathetic activity would lead to hyperphagia and in the absence of another compensatory mechanism would produce obesity. The basis for this hypothesis is evidence that neurotransmitters, neuropeptides and many drugs which affect food intake have a reciprocal effect on food intake and the sympathetic nervous system. 1 ± 3 This paper will examine both the experimental data which underpins this hypothesis and its clinical implications.
The sympathetic nervous system and food intake: experimental observations
The sympathetic nervous system (SNS) is a segmented multifunctional system which can be evaluated in any one of several ways. 4 Physiological responses are one approach. Changes in blood pressure, heart rate, heart rate variability and pupillary response to light are a few of the physiological end-points that can be used to assess sympathetic and parasympathetic activity. Norepinephrine secretion, turnover and excretion are more proximate since they are looking at the neurotransmitter for sympathetic responses. Sympathetic agonists and receptor antagonists can also be used to tease apart the system. Finally, electrical recording in vivo from the mixed peroneal nerve in humans (muscle sympathetic nerve activity or MSNA) or from nerves innervating brown adipose tissue (BAT) in animals can be used. We will review data using several of these methods.
The classical teaching has been that the SNS functions in an off-and-on manner. Accumulating data suggest, however, that this is not correct but rather that the system functions in several separable subdivisions. For example, sympathetic activity in the extremities can be disassociated from the visceral sympathetics. During starvation for 24 or 48 h, the activity of the visceral sympathetic nerves is reduced, 2, 5 but there is no decrease in the sympathetic activity in the extremities. 6 A second division involves the sympathetic nerves to BAT and the heart. A third division is the sympatho-adrenal system which controls the release of epinephrine from the adrenal medulla. A fourth separation is shown in response to IL-6. When this cytokine is injected, the turnover of norepinephrine (NE) in lung and spleen is increased but there is no increase in other tissues. Finally, there is some evidence to suggest that the activity of the thoracic sympathetic nerves to BAT and the heart can be separated from the activity of visceral sympathetic nerves.
In experimental animals, food intake and activity of sympathetic nerves to BAT are reciprocally related. 1 ± 3 The data supporting this hypothesis are summarized in Table 1 . The data suggesting this hypothesis came ®rst from studies of animals with hyperphagic obesity following lesions in the ventromedial hypothalamus (VMH) and lateral hypothalamus (LH). Damage to the VMH altered the size of salivary glands, 7 blunted the mobilization of fatty acids, 8, 9 and led to involution of BAT. It was then demonstrated that the turnover of NE to BAT 10 and electrical ®ring of nerves to BAT was reduced. 11, 12 Whether hyperphagia is present or not, the hyperphagia and obesity following a VMH lesion is associated with a reduction in activity of the SNS, decreased thermogenesis in BAT and delayed satiety. 7 ± 12 In contrast to the reduced SNS activity, the activity of the parasympathetic nervous system is increased in VMH-lesioned animals 13 ± 16 and in the obese faafa rat. 17 The lateral hypothalamus also participates in the reciprocal relation of sympathetic activity and feeding. Stimulation of the LH induces stimulus-bound feeding and weight gain. 18 In contrast, lesions in the LH produce a characteristic acute hypophagia 19 and an increase in the activity of the SNS, 20, 21 which is followed by permanent reduction in body weight. Hypophagia after an LH lesion (or treatment with fen¯uramine) does not occur if the weight of the test subjects is acutely reduced by food restriction to a level below what would be achieved after the lesion or drug treatment. 22, 23 In such animals, food intake is normal, suggesting that the LH lesion or fen¯ura-mine 24 may interfere with a regulatory feedback system. The LH is also a site for regulation of the autonomic nervous system responses to feeding, having reciprocal effects to those of the VMH. 15 The discovery of the peptide, orexin, as a G-protein coupled signal which stimulates food intake may provide a molecular basis for these changes. 25 The broader physiological signi®cance of the experiments described above in lesioned animals was suggested in a study of spontaneously feeding animals. 26 The food intake of six animals was measured every 6 h and the sympathetic activity recorded immediately afterward. There was a highly signi®cant inverse relationship between food intake and sympathetic activity which is shown in Figure 1 . From these studies we hypothesized that there was a reciprocal relationship between food intake and SNS activity to BAT which is depicted in Figure 2 . This relationship has since been demonstrated repeatedly.
A number of neurochemicals, neuropeptides and drugs demonstrate the reciprocal relationship between food intake and sympathetic activity after central or peripheral administration (Table 1) . Neuropeptide Y (NPY) is the most potent peptide stimulator of feeding that has been described to date. 27 When given chronically into the cerebral ventricles, either by infusion or by multiple daily injection, NPY produces a dosedependent stimulation of food intake. Food intakes of 50 gaday, more than twice control levels, may be sustained over the full experimental period of 7 ± 10 days by rats. With longer infusion, food intake of NPY-treated rats levels off at an elevated level. Increased deposition of body fat accompanies this hyperphagic state. The experiments clearly demonstrate that exogenous NPY can override all counterregulatory systems of satiety and body weight regulation and are consistent with the increased motivation to feed that is induced by this peptide. NPY also reduces thermogenesis from BAT at the same time that it increases food intake. Food intake and sympathetic activity GA Bray
The robust relationship between food intake and SNS of NPY-treated rats is shown in Figure 3 . NPY decreases sympathetic activity to BAT in a dosedependent fashion after injection into the third ventricle or into the paraventricular nucleus (PVN). 28 ± 30 NPY also inhibits UCP-1 expression in BAT. The stimulation of food intake by NPY can be blocked by the opioid antagonist, naloxone. In studies on the anatomic structures involved in the response to NPY, Kotz et al 31 found that naltrexone, injected into either the nucleus of the tractus solitarius in the hind brain or into the amygdala, blocked both the rise in food intake and the inhibition of SNS activity. This indicates that these two effects of NPY are coupled.
Several other peptides, neurotransmitters and drugs summarized in Table 1 show this reciprocal relationship. b-Endorphin 32 and galanin 33 are two other peptides that increase food intake and depress SNS activity to BAT. On the other hand, leptin, 34, 35 corticotrophin-releasing hormone (CRH), 36 cholecystokinin, 37 enterostatin 33 and bombesin 38 decrease food intake and stimulate sympathetic activity to BAT. The appetite suppressant drugs fen¯uramine 24 and sibutramine 39 both decrease food intake and stimulate the SNS to BAT. Nicotine is of particular interest. Nicotine is an alkaloid which acts on a group of receptors called nicotinic receptors. It is a drug which reduces food intake and increases thermogenesis. 40, 41 Of the neuropeptideaneurochemical transmitters that effect food intake acutely, only norepinephrine, 42 NPY, 27 galanin, 43 glucagon-like peptide 1 6 ± 29 (GLP-1), 44 enterostatin, 45 MCH, 46 CRH 36,47 ± 50 and insulin 51 ± 54 have been investigated for their chronic effects in animals. CRH abolishes the hyperphagia of genetic 29,36,47 ± 49 and VMH obesity 50 and may modulate feeding after treatment with interleukin 1b and other cytokines. Insulin, given intracerebroventricularly, reduces food intake of lean rats 52, 53 but not obese fatty rats 54 and this effect only occurs in animals eating a high carbohydrate diet. 53 The robust reciprocal relationship that has been demonstrated between food intake and the activity of the thermogenic component of the SNS suggests the possibility of a sympathetic feedback system involved in the regulation of food intake ( Figure 2 ). Additional support for this hypothesis has come from Figure 1 Sympathetic activity and food intake. Food intake of individual rats was measured over 4 h prior to measuring the electrical ®ring rate of nerves to brown adipose tissue. Groups of six rats were measured during each 6 h interval of the 24 h period with animals maintained on their usual light cycle and access to food and water. it also reduced food intake, 56 con®rming data from several other labs using both rats and mice.
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The effect of the b 3 -agonist on food intake is partially blocked by propranolol, a non-speci®c b-adrenergic antagonist. 56 In mice with a knock-out of the b 3 -adrenergic receptor, the suppression of food intake by a b 3 -agonist is abolished. 58 However, knock-out of the uncoupling protein which transduces b 3 -signals to heat production in BAT does not block the effect of the b 3 -agonist on food intake suggesting that it is not directly related to heat production by BAT. 60 The relation of these receptors to food intake was explored using selective b-agonists. 61 Clenbuterol, a b 2 -agonist, was the most potent inhibitor of food intake. This occurred at a dose well below the dose that stimulated thermogenesis. In contrast, the b 1 -and b 3 -agonists were relatively weak inhibitors of food intake. 61 The inhibition of food intake by clenbuterol was blocked by nadolol, a b 2 -adrenergic-blocking drug that does not enter the CNS, suggesting that there are peripheral b 2 -adrenergic receptors that can reduce food intake.
We have recently examined the effect of a b 3 -agonist on food intake in mice made obese with goldthioglucose (GTG). 62 The GTG obese mice showed a greater reduction in food intake than their corresponding lean littermates. The presence of transgenes overexpressing glycerol-3-phosphate dehydrogenase or uncoupling protein-1 did not modify the response to the b 3 -agonist. Vagotomy with capsaicin also did not reduce the attenuation of food intake by the b 3 -agonist. 63 The reciprocal relationship between sympathetic activity and food intake raises the question of cause and effect; of whether the change in food intake or SNS activity comes ®rst or whether they are consequences of the same central process. When the electric ®ring of nerves to BAT was measured, the changes in electrical activity were rapid, suggesting that the SNS might be inhibiting food intake. Simultaneous measurement of SNS and food intake may answer this question. The response to prostaglandin E 2 has been studied in conscious animals in which electrical ®ring rate of nerves to BAT and food intake could be measured simultaneously. PGE-2 injected into the lateral brain ventricle caused an increase in temperature and termination of feeding. Food intake ceased just as temperature was starting to rise, suggesting that the sympathetic activation acts as a satiety signal. 64 Thus, blockade of SNS appears to attenuate the feeding response. We have tested this hypothesis with CRH and NPY. 65 CRH stimulates SNS activity and reduces food intake. 66 If SNS stimulation inhibited food intake, then blockade of the SNS with a ganglionic blocking drug would be predicted to reduce the inhibitory effect of CRH. Using hexamethonium to block ganglionic nerve transmission in the SNS, the CRH suppression of food intake was attenuated. 65 Conversely, NPY stimulates food intake and suppresses SNS activity to BAT. When the effect of SNS stimulation was mimicked by a b 3 -agonist (CL316,243) 65 or leptin, 67 the stimulation of food intake by NPY was attenuated. These data suggest that one component of sympathetic efferent output may tonically inhibit feeding and that to initiate food intake this inhibitor must be removed. Enhanced tonic activity of this sympathetic inhibitor would reduce food intake further. Food intake and sympathetic activity GA Bray Recent experiments in our laboratory suggest that b 3 -adrenergic receptors in the gut, heart or pituitary may be involved in reducing food intake rather than b 3 -receptors in BAT. 65 When NPY is given centrally to rats deprived of food, there is a diuresis which is blocked by vasopressin (AVP). The diuresis produced by NPY in non-fed animals is also blocked by a b 3 -agonist or by food. There are several possible interpretations of this experiment. First the b 3 -agonist might act directly on the kidney in the same way as AVP or act on the heart to release atrial natriuretic peptide. Second the b 3 -agonist might act on the pituitary to release AVP. Finally the b 3 -agonist might act on the gut to produce the same afferent signals that food produces to reduce the diuresis that would occur if NPY were given without food. We prefer this latter interpretation.
Glucocorticoid and the sympathetic nervous system
Glucocorticoid secretion from the adrenal gland is essential for the development of obesity. 15 Removal of the adrenal cortex is suf®cient to impair the development of all experimental obesities. 15 The obesity of the obaob mouse, the dbadb mouse and the fatty rat do not progress after adrenalectomy. 15 Thus, the metabolic components of leptin de®ciency (obaob), 68 leptin receptor de®ciency ( faafa; dbadb) 69, 70 and overexpression of agouti protein (yellow mouse) 71 are dependent on adrenal glucocorticoids. However, the infertility of these animals is not restored by adrenalectomy, 72 suggesting that there is another function for leptin and its receptor.
One way glucocorticoids might modulate body fat stores is through CRH receptors. CRH-1 receptors modulate CRH effects on pituitary secretion of ACTH. CRH-2 receptors, however, are better candidates for regulation of feeding since they modulate effects of urocortin or CRH in regions outside the PVN and pituitary. Infusion of CRH into the ventricular system of fatty rats 47 ± 49 or rats with VMH lesions 50 reduces food intake, increases sympathetic activity to BAT and lowers body weight (see Figure 5 ).
The fact that adrenalectomy reverses or blocks the progression of all forms of experimental obesity, 15 would suggest that glucocorticoids must modulate sympathetic activity. Adrenalectomy increases sympathetic activity in leptin de®cient (obaob) mice, 73 and leptin receptor de®cient rats 74, 75 and mice. 76 Glucocorticoids given acutely will decrease sympathetic activity. 77 On the other hand, adrenalectomy or acute intracerebroventricular (ICV) CRH will increase sympathetic activity and reduce food intake (Table 1) . To study the effect of adrenalectomy, the electrical activity of sympathetic nerves innervating BAT was measured. Food intake was recorded in the 2 h before measuring SNS activity. The fall in food intake and reciprocal rise in sympathetic activity can be seen in Figure 6 . Glucocorticoid de®ciency reverses the effects of leptin de®ciency, suggesting that glucocorticoids are essential in modulating activity of the sympathetic nervous system. Since adrenalectomy increases sympathetic activity, one might anticipate that adding other agents which stimulate sympathetic activity might augment the decrease in food intake and body weight. This prediction has been tested in two settings. The ®rst was treatment of adrenalectomized rats with fen¯uramine. This combination of treatments produced profound weight loss. 78 Similarly, treatment of adrenalectomized animals with leptin produces augmented weight loss. 79 
Sympathetic activity and food intake: clinical implications
A number of studies have examined the relationship between sympathetic activity and human obesity. The conclusions have been dependent on the methods used. 80, 81 Using plasma or urinary norepinephrine gives no consensus on whether SNS activity changes with obesity. Only about 30% of the studies found lower NE excretion in the obese. In a carefully controlled study, Peterson et al 82 have shown an inverse relationship between urinary norepinephrine excretion and body mass index (BMI). Using the muscle sympathetic activity (MSNA) as a gauge of sympathetic activity has also demonstrated inconsistent relationship between SNS and obesity. In Pima Indians, for example, the MSNA is lower than in Caucasians and does not rise with body weight. 83 In studies by Scherrer et al, MSNA was positively related to BMI. 84 We have examined the relationship of SNS to obesity in two experiments. Using the heart rate variability in the standing and recumbent positions, we found that individuals with upper body obesity, as indicated by a higher waist-to-hip circumference ratio (WHR), had higher SNS activity than individuals with lower body obesity. 85 Second, we have found an inverse relationship between SNS by Figure 5 Sites where adrenalectomy could alter food intake and the function of the sympathetic nervous system. Adrenalectomy may have its effects either through increased synthesis and secretion of CRH andaor urocortin or through upregulation of the CRH 2 receptor.
Food intake and sympathetic activity GA Bray heart rate variability and body fat ( Figure 7 ). Thus, depending on the method used, the reduction in SNS activity can be identi®ed, at least in some obese individuals. A reduction in thermic responses, modulated by the sympathetic nervous system, has been postulated as a way to conserve energy. Post-obese subjects, ie those who have reduced with diet, might be expected to demonstrate reduced thermic responses. Plasma NE, however, is normal in post-obese women eating medium or high fat diets. Post-obese subjects also have a normal thermogenic response to cold and to badrenergic stimulation. 80 When carbohydrate diets are used, sympathetic activity in the post-obese varies with carbohydrate content of the diet, and this is more pronounced in the post-obese than in lean subjects. Thus, diet seems to have an important role in determining sympathetic activity, and the stimulatory effect of carbohydrate may be exaggerated in the post-obese.
Low sympathetic activity is a predictor of obesity in the Pima Indians. 86 Blaak et al 87 found an impaired thermic response to the b-agonist isoprenaline infused in obese subjects as compared with lean ones. In women undergoing a 36 week weight loss program, Astrup et al 88 found that post-prandial norepinephrine was positively associated with maximal weight loss. The fact that the relationship between baseline plasma NE and weight loss persists after controlling for 24 h energy expenditure and fat oxidation suggests that the effect may be exerted at least in part on food intake.
The effects of nicotine also argue for a clinical role of the SNS in modulating food intake and SNS activity. It has been known for a long time that smokers are lighter than non-smokers. 89 Smoking and nicotine increase thermogenesis. 90 When smokers stop smoking they gain weight, which is the result of increased food intake and reduced energy expenditure. 91 The inhibitory effect of the sympathetic nervous system in humans is suggested by three other studies. In one study, the change in hunger ratings after different types of meals was related to the change in area under the NE curve. 92 There was a highly signi®cant inverse relationship consistent with Most Obesities kNown Are Low In Sympathetic Activity (the MONA LISA) hypothesis. The other two observations come from clinical trials using a b 3 -agonist (BRL-26830A) 93 or ephedrine and caffeine. 94 In the clinical trial of BRL-26830A 93 the drug-treated group lost 4.0 kg more in 18 weeks than the placebo control group. This extra fat loss translates into a loss of 36,000 kcal or 2250 kcalaweek more than placebo. This is approximately 300 kcaladay which would be more than a 10% increase in energy expenditure. However, the drug only produces an average of 5%, suggesting that 50% or more of the fat loss was associated with reduced food intake. In the study of ephedrine and caffeine by Astrup et al, 94 they estimated that the thermogenic changes only accounted for 20 ± 25% of the fat loss. Thus, reduced food intake must have accounted for the other 75 ± 80% of the reduced energy. Collectively, these studies argue that Food intake and sympathetic activity GA Bray the suppression of food intake by the sympathetic nervous system may be an important effect of these thermogenic drugs.
A number of studies have linked a codon trp 64 arg (W64R) polymorphism in the b 3 -adrenergic receptor gene to obesity, although there is considerable variation among populations. This mutation has been linked to a reduction in resting metabolic rate (RMR) in Pima Indians, 95 in the capacity to gain weight in a French population 96 and several other groups 97 and there is a higher incidence of this mutation in Japanese obese individuals compared with lean subjects. 98 Others can ®nd no relationship of this mutation to obesity. 97 Investigators have sought to interpret their data in relation to adrenergic effects on lipolysis, but it is clearly possible that this linkage could re¯ect a b 3 -adrenergic modulation of food intake. Figure 8 is a schematic diagram of possible places where b 2 and b 3 -adrenergic agonists might work. From a number of studies, the hypothalamic perifornical area (PFA) is demonstrably an important site for noradrenergic control of food intake. 99 The input to this area comes in part from the locus coeruleus and possibly other ascending noradrenergic pathways. 100 The perifornical area is depicted as inhibiting the motor pattern generator (MPG) which is the driver and integrator of feeding activities. When activated, the MPG leads to the ingestion of food which enters the gastro-intestinal (GI) track for digestion and absorption. From the studies of b 3 -agonists given to hungry rats, another site for action of the b 3 -agonist might be the gut, with messages relayed to the brain by vagal or afferent sympathetic signals. Recent studies by Bray et al 101 make these signaling systems unlikely, since mice vagotomized with capsaicin or treated with a ganglionic blocking drug, hexamethonium, still show a reduction of food intake when treated with b 3 -agonists. The gut signals which arise from digestion of food are sent along the vagus to the nucleus tractus solitarius (NTS) where there are ascending messages to the amygdala and PVN.
An action of b 3 -agonists on brown and white adipose tissue (WATaBAT) is well known. The WAT is the site for a generation of leptin, which is a key signal from the periphery to the brain and whose production in fat cells is stimulated by glucocorticoids and insulin, and inhibited by adrenergic signals. Circulating leptin activates Lep receptors in the arcuate nucleus (ARC) which may enhance the post-translational conversion of proopiomelanocortin (POMC) to a-MSH. On the other hand, leptin appears to reduce the production of NPY also by acting on the ARC. These two peptide signals act on the PVN, and possibly the VMH. After eating a meal, afferent vagal signals to the NTS are transmitted to the nucleus of the tractus VMH which then signals to BAT. Thus, there are clearly peripheral and central sites at which b-adrenergic agonists can inhibit food intake as part of a feedback system producing satiety.
In the preceding paragraphs we have argued that the SNS plays an important role in the modulation of food intake ( Figure 8 ). When food is ingested the activation of the SNS may be one part of the satiety system. The converse side of this argument is that, as the time since food ingestion lengthens, the activity of the SNS declines, serving to lower the threshold at which future meals may occur. Thus, the low sympathetic activity observed in fasting is associated, in this model, with a low threshold for eating and, when food is available, more food is eaten. This reciprocal relationship between food intake and sympathetic activity occurs in humans and animals. Experimentally, Most Obesities kNown Are Low in Sympathetic Activity (the MONA LISA hypothesis). The demonstration in clinical studies that thermogenic' drugs reduce food intake, which accounts for more than 50% of their effect, suggest that tonic stimulation of the b 3 receptors may be important in tonic control of body weight.
Some investigators have argued that, because exposure to cold or ingestion of a palatable diet in young animals increases food intake and stimulates the SNS at the same time, that the reciprocal relationship of food intake and the SNS described by the MONA LISA hypothesis has no physiological meaning. This argument is similar to saying that because severe stress or burns increase ACTH and cortisol when cortisol is already high means that there is no feedback system regulating ACTH and cortisol. Rather, the high cortisol and high ACTH in the face of stress indicate that there is both a feedback and direct drive control of ACTH output. Similarly, the feedback model shown in Figure 8 can be overridden in special circumstances such as cold or highly palatable diet. The validity of the feedback system still remains under most circumstances, and provides helpful insights in planning for thermogenic therapy as a treatment of obesity.
